0      0

JL1113EH - JL1113EH: Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

‐ Oct 23, 2023 3:00pm

Full author listing

Nancy L. Bartlett, M.D1, Laurie H. Sehn, M.D2, Matthew Matasar, M.D3, Stephen J. Schuster, M.D4, Sarit Assouline, M.D5, Pratyush Giri, MBBS6, John Kuruvilla, M.D7, Miguel Canales, M.D8, Sascha Dietrich, M.D9, Keith Fay, MBChB10, Matthew Ku, MBBS11, Loretta Nastoupil, M.D12, Michael C. Wei, M.D, Ph.D13, Shen Yin, Ph.D13, Iris To, PharmD13, Huang Huang, MSc14, Juliana Min15, Elicia Penuel, Ph.D13, L. Elizabeth Budde, M.D, Ph.D16

1Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA; 2BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada; 3Memorial Sloan Kettering Cancer Center, New York, NY, USA; 4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; 5Jewish General Hospital, McGill University, Montreal, QC, Canada; 6Royal Adelaide Hospital, Adelaide, Australia; 7Princess Margaret Cancer Centre, Toronto, ON, Canada; 8Hospital Universitario La Paz, Madrid, Spain; 9Universitat Heidelberg, Heidelberg, Germany; 10St Vincent's Hospital and Royal North Shore Hospital, Sydney, Australia; 11St Vincent's Hospital, University of Melbourne, Melbourne, Australia; 12MD Anderson Cancer Center, Houston, TX, USA; 13Genentech, Inc., South San Francisco, CA, USA; 14F. Hoffmann-La Roche Ltd, Mississauga, Canada; 15Roche Products Ltd, Welwyn Garden City, United Kingdom; 16City of Hope, Duarte, CA, USA


You must be logged in and own this session in order to post comments.